ICD-10-PCS › X
ICD-10-PCS codes starting with X
734 codes, page 6 of 8. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| XW033G4 | Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4 through FY2023 | Retired |
| XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033G6 | Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW033G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033H4 | Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4 through FY2023 | Retired |
| XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033H6 | Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW033H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033J7 | Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033K5 | Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW033K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033K9 | Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW033L6 | Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW033L7 | Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033MA | Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033N5 | Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW033N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033NA | Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033P9 | Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW033PB | Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW033Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033Q9 | Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW033QB | Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW033R9 | Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW033RB | Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW033S5 | Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033U5 | Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW033W5 | Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033WB | Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW04306 | Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW04308 | Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0430B | Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW0431B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW04321 | Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW04326 | Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW04331 | Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW04336 | Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW0433A | Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW04341 | Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW0434A | Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW04351 | Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW04357 | Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW04358 | Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0435A | Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW04366 | Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW04367 | Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW04368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0436C | Introduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12 | Valid |
| XW04372 | Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2 | Valid |
| XW04377 | Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW04378 | Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW04387 | Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW04388 | Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0438A | Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW04392 | Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2 through FY2022 | Retired |
| XW04396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW04398 | Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0439A | Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043A3 | Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3 through FY2022 | Retired |
| XW043A6 | Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043A7 | Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 | Valid |
| XW043B6 | Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043B7 | Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW043BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043C3 | Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3 through FY2021 | Retired |
| XW043C6 | Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043CA | Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043D6 | Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043E5 | Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043E6 | Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043F3 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3 | Valid |
| XW043F5 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043F6 | Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW043FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043FB | Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW043G4 | Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4 through FY2023 | Retired |
| XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043G6 | Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW043G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043H4 | Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4 through FY2023 | Retired |
| XW043H5 | Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043H6 | Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW043H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043J7 | Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043K5 | Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW043K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043K9 | Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW043L6 | Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW043L7 | Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043MA | Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043N5 | Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW043N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW043NA | Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW043P9 | Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW043PB | Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW043Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |